100
Participants
Start Date
June 21, 2018
Primary Completion Date
May 1, 2023
Study Completion Date
May 31, 2026
Vinorelbine
work by interfering with cell division, which leaves the tumor unable to grow and spread
Trastuzumab
trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2.
Avelumab
monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein
Utomilumab
Utomilumab is an antibody designed to stimulate the body's immune system to fight cancer cells
Memorial Sloan-Kettering Cancer Center, New York
Montefiore Medical Center, The Bronx
University of Pennsylvania, Philadelphia
Georgetown University Medical Center, Washington D.C.
Johns Hopkins University, Baltimore
Duke University Medical Center, Durham
University of Alabama at Birmingham, Birmingham
Vanderbilt University Medical Center, Nashville
Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis
University of Chicago Medical Center, Chicago
Baylor College of Medicine, Houston
MD Anderson Cancer Center, Houston
University of California San Francisco, San Francisco
University of Washington Fred Hutchinson Cancer Care, Seattle
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
University of Carolina at Chapel Hill, Chapel Hill
Collaborators (2)
Pfizer
INDUSTRY
Breast Cancer Research Foundation
OTHER
Johns Hopkins University
OTHER
Adrienne G. Waks
OTHER